RVPH — Reviva Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Reviva Pharmaceuticals Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Reviva Pharmaceuticals Q2 EPS USD -0.12
Reviva Pharmaceuticals Holdings Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals Holdings To Offer Shares And Warrants In Public Offering
Brief: Reviva Announces Positive Full Dataset For 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
Brief: Reviva Pharmaceuticals Holdings Inc - Enters Into At Market Issuance Sales Agreement - SEC Filing
Reviva Pharmaceuticals Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Reviva Pharmaceuticals Q1 EPS USD -0.13
Reviva Pharmaceuticals Holdings Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals Holdings Files For Non-Timely 10-K - SEC Filing
Brief: Reviva Pharmaceuticals FY EPS USD -0.9
Brief: Applied Therapeutics Appoints John H. Johnson As Executive Chairman
Brief: Reviva Prices $18 Mln Public Offering Of Common Stock And Warrants
Brief: Reviva Announces Proposed Public Offering
Brief: Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. reports results for the quarter - Earnings Summary
Brief: Reviva Pharmaceuticals Q3 EPS USD -0.25
Brief: Reviva Announces Enrollment Update For Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 25 cents a share - Earnings Preview